HER-3 overexpression is prognostic of reduced breast cancer survival: A study of 4046 patients

Annals of Surgery

Volumn 251, Issue 6, 2010, Pages 1107-1116

  Chiu, Connie G ^a   Masoudi, Hamid ^a   Leung, Samuel ^a   Voduc, David K ^a,b   Gilks, Blake ^a   Huntsman, David G ^a,b,c   Wiseman, Sam M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c Centre for Translational and Applied Genomics   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY; TUMOR ABLATION; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 77953022049     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181dbb77e     Document Type: Article

References (64)

1. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980-991.
2. Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev. 2001;27:137-142.
3. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-978.
4. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT!for early breast cancer. J Clin Oncol. 2005; 23:2716-2725.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overex-presses HER2. N Engl J Med. 2001;344:783-792.
6. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
7. Olayioye MA. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001;3:385-389.
8. Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA. 2003;100:8933-8938.
9. Sepp-Lorenzino L, Eberhard I, Ma Z, et al. Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene. 1996; 12:1679-1687.
10. Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. Ann Oncol. 2001;12(suppl 1):S9-S13.
11. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996;16:5276-5287.
12. Beerli RR, Graus-Porta D, Woods-Cook K, et al. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol. 1995;15:6496-6505.
13. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimer-ization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997;16:1647-1655.
14. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996;15:2452-2467. (Pubitemid 26151185)
15. Horan T, Wen J, Arakawa T, et al. Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3. J Biol Chem. 1995;270:24604-24608.
16. Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA. 1999;96:4995-5000.
17. Zaczek A, Brandt B, Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol. 2005;20:1005-1015.
18. Guy PM, Platko JV, Cantley LC, et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA. 1994;91:8132-8136.
19. Pinkas-Kramarski R, Shelly M, Guarino BC, et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol. 1998;18:6090-6101.
20. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12(suppl 1):S3-S8.
21. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003;284:54-65.
22. Siegel PM, Ryan ED, Cardiff RD, et al. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 1999;18:2149-2164.
23. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68:5878-5887.
24. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phospha-tidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 1994;13:2831-2841.
25. Wiseman SM, Makretsov N, Nielsen TO, et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 2005;103:1770-1777.
26. Olivotto A, Coldman AJ, Hislop TG, et al. Compliance with practice guidelines for node-negative breast cancer. J Clin Oncol. 1997;15:216-222.
27. Cheang MC, Treaba DO, Speers CH, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24:5637-5644.
28. Turbin DA, Leung S, Cheang MC, et al. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat. 2008;110:417-426.
29. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376.
30. Jensen KC, Turbin DA, Leung S, et al. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat. 2008;112:453-459.
31. Rajput AB, Turbin DA, Cheang MC, et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 2008;107:249-257.
32. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002;117: 723-728.
33. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006;4(suppl 3):S1-S22; quiz S23-S24.
34. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Fort Washington, PA: National Comprehensive Cancer Network; 2007. Version. 2.2007.
35. Travis A, Pinder SE, Robertson JF, et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer. 1996;74:229-233.
36. Suo Z, Yang H, Mei Q, et al. Type 1 protein tyrosine kinases in Chinese breast carcinomas: a clinicopathologic study. Int J Surg Pathol. 2001;9:177-187.
37. Naidu R, Yadav M, Nair S, et al. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer. 1998;78:1385-1390.
38. Gasparini G, Gullick WJ, Maluta S, et al. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma\an immunocytochemical study. Eur J Cancer. 1994;30A:16-22.
39. Lee Y, Cho S, Seo JH, et al. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast. Am J Clin Pathol. 2007;128:1041-1049.
40. Aubele M, Auer G, Walch AK, et al. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer. 2007;96:801-807.
41. Esteva FJ, Hortobagyi GN, Sahin AA, et al. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res. 2001;7:171-177.
42. Sassen A, Rochon J, Wild P, et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res. 2008;10:R2.
43. Suo Z, Risberg B, Kalsson MG, et al. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol. 2002;196:17-25.
44. Bianchi S, Palli D, Falchetti M, et al. ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. J Cell Physiol. 2006;206: 702-708.
45. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer. 2004;91:1532-1542.
46. Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290-297.
47. Srinivasan R, Gillett CE, Barnes DM, et al. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res. 2000;60:1483-1487.
48. Zaczek A, Welnicka-Jaskiewicz M, Bielawski KP, et al. Gene copy numbers of HER family in breast cancer. J Cancer Res Clin Oncol. 2008;134:271-279.
49. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998; 3:237-252.
50. Lemoine NR, Barnes DM, Hollywood DP, et al. Expression of the ERBB3 gene product in breast cancer. Br J Cancer. 1992;66:1116-1121.
51. Kalemi TG, Papazisis KT, Lambropoulos AF, et al. Expression of the HER family mRNA in breast cancer tissue and association with cell cycle inhibitors p21(waf1) and p27(kip1). Anticancer Res. 2007;27:913-920.
52. Lodge AJ, Anderson JJ, Gullick WJ, et al. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol. 2003;56:300-304.
53. Hudelist G, Singer CF, Manavi M, et al. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat. 2003;80:353-361.
54. Giltnane JM, Moeder CB, Camp RL, et al. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer. 2009;115:2400-2409.
55. Jambhekar NA, Chaturvedi AC, Madur BP. Immunohistochemistry in surgical pathology practice: a current perspective of a simple, powerful, yet complex, tool. Indian J Pathol Microbiol. 2008;51:2-11.
56. True LD. Quality control in molecular immunohistochemistry. Histochem Cell Biol. 2008;130:473-480.
57. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
58. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393-10398.
59. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
60. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353: 1673-1684.
61. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
62. Robinson AG, Turbin D, Thomson T, et al. Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clin Breast Cancer. 2006;7:254-261.
63. van der Horst EH, Murgia M, Treder M, et al. Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies. Int J Cancer. 2005;115:519-527.
64. Allen LF, Eiseman IA, Fry DW, et al. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol. 2003;30(5 suppl 16):65-78.